nib Group closes nib Travel sale, banking $97.6 million in proceeds
nib Holdings Limited has confirmed completion of both previously announced sale transactions of nib Travel, representing the final major milestone in the divestment of its travel insurance businesses.
The first transaction saw nib complete the sale of its Australian and New Zealand travel insurance businesses to Allianz Partners, effective 17 September 2026. The second transaction completed the sale of its World Nomads international travel insurance business to International Medical Group (IMG), a wholly-owned subsidiary of SiriusPoint, effective 30 September 2026.
The World Nomads divestment to SiriusPoint was announced in February 2026 for $67.5 million AUD, representing the first leg of a two-part exit strategy that nib has now brought to a close with the completion of both transactions.
Combined cash consideration received on completion was $97.6 million, as outlined in the company’s FY2026 Full Year Results Presentation. Up to $10 million in eligible deferred consideration remains available in FY28.
When big ASX news breaks, our subscribers know first
Sharpening focus on core health insurance
The divestment positions nib to simplify its portfolio and concentrate resources on its core health insurance and health-related businesses, reducing operational complexity across the group.
Ed Close, Managing Director and CEO
“The completion of these transactions marks an important milestone for nib, further strengthening our focus on our core health insurance and health-related businesses. We are pleased to have transferred these travel insurance businesses to partners with deep industry expertise, global scale and strong growth ambitions.”
Importantly for existing nib customers, the company will continue to distribute nib-branded travel insurance in Australia and New Zealand under a long-term strategic partnership with Allianz Partners. Transitional services and support arrangements will also remain in place for both transactions for a period to support continuity for customers and partners.
What is a portfolio simplification strategy, and why does it matter for nib investors?
When a listed company divests a non-core business, the goal is typically to redirect capital, management attention, and operational resources toward the areas where it has the greatest competitive advantage. Selling a business that sits outside that core focus can improve earnings quality and reduce the drag of managing structurally different operations.
Travel insurance and health insurance are quite different businesses. Travel insurance revenues are sensitive to fluctuations in tourism demand and global events, whereas health insurance operates under a more stable, needs-driven demand profile with a distinct regulatory framework. This difference in risk profile means that holding both under one roof can introduce earnings volatility that long-term investors find difficult to assess.
For nib specifically, exiting travel insurance reduces exposure to that cyclical variability and allows management to concentrate capital on its health insurance operations. A tighter, more focused business typically earns a cleaner earnings multiple from the market, and reduces complexity risk for shareholders over the long term.
Proceeds deployed — special dividend on the way
nib outlined its planned use of the sale proceeds in its FY2026 Full Year Results Presentation. Key elements of the capital return and proceeds summary include:
The nib FY2026 full year results, released in August 2026, set the financial backdrop for these transactions, with underlying operating profit rising 9.1% to $260.9 million and the Board lifting its target dividend payout ratio to 65-75% as capital management optionality expanded.
- Cash proceeds received: $97.6 million (combined across both transactions)
- Eligible deferred consideration: up to $10 million (FY28)
- Special dividend: 5.0 cents per share, included in the FY26 final dividend, to be paid to shareholders on 7 October 2026
- Further capital management optionality: available
The near-term payment of the special dividend on 7 October 2026 provides a tangible and immediate benefit for shareholders following the conclusion of the divestment process.
The table below summarises the two completed transactions side by side.
| Transaction | Asset Sold | Buyer | Completion Date | Consideration Notes |
|---|---|---|---|---|
| Transaction 1 | AU & NZ travel insurance | Allianz Partners | 17 September 2026 | Part of $97.6m combined cash consideration |
| Transaction 2 | World Nomads (international) | IMG (SiriusPoint subsidiary) | 30 September 2026 | Part of $97.6m combined cash consideration |
With both transactions now complete and a special dividend scheduled for payment within days of this announcement, nib’s strategic repositioning around its core health insurance operations is effectively finalised.
Stay Ahead on ASX Healthcare and Finance News
Get FREE breaking ASX alerts delivered to your inbox within minutes of release, complete with in-depth analysis already done for you. Join 20,000+ subscribers who never miss market-moving news the moment it breaks. Click the “Free Alerts” button at Big News Blast to start receiving real-time coverage across Healthcare, Finance, and beyond.